Lebrikizumab Provides Progressive Improvements in Skin Clearance and Itch Relief Over One Year in Patients with Atopic Dermatitis

Main Article Content

April Armstrong
University of California, Los Angeles, USA

Kamran Ghoreschi
Charité University Hospital, Berlin, Germany, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Berlin, Germany

David Rosmarin
Indiana University School of Medicine, Indianapolis, USA

Todd Schlesinger
Clinical Research Center of the Carolinas, Charleston, USA

Alan Irvine
Children's Health Ireland, Dublin, Ireland

Anthony Bewley
The Royal London Hospital, London, UK

Marta Casillas
Eli Lilly and Company, Indianapolis, USA

Gaia Gallo
Eli Lilly and Company, Indianapolis, USA

Yuxin Ding
Eli Lilly and Company, Indianapolis, USA

Chenjia Xu
Eli Lilly and Company, Indianapolis, USA

Ignasi Pau-Charles
Almirall S.A., Barcelona, Spain

Eric Simpson
Oregon Health & Science University, Portland, USA

Keywords

Lebrikizumab, atopic dermatitis, itch

References

1. Grant L, et al. Dermatitis. 2019;30:247-254.

2. Okragly AJ, et al. Dermatol Ther (Heidelb). 2023;13:1535-1547.

3. Blauvelt A, et al. Br J Dermatol. 2023;188:740-748.

4. Silverberg JI, et al. N Engl J Med. 2023;388:1080-1091.

5. Revolutionizing Atopic Dermatitis, 11-13 December 2021. Br J Dermatol. 2022;186:e135-185.

Article Sidebar

PDF
Published
Nov 13, 2023
DOI https://doi.org/10.25251/skin.7.supp.278

Article Details

How to Cite
[1]
Armstrong, A. , Ghoreschi, K. , Rosmarin, D. , Schlesinger, T. , Irvine, A. , Bewley, A. , Casillas, M. , Gallo, G. , Ding, Y. , Xu, C. , Pau-Charles, I. and Simpson, E. 2023. Lebrikizumab Provides Progressive Improvements in Skin Clearance and Itch Relief Over One Year in Patients with Atopic Dermatitis. SKIN The Journal of Cutaneous Medicine. 7, 6 (Nov. 2023), s278. DOI:https://doi.org/10.25251/skin.7.supp.278.
Issue
Vol. 7 No. 6 (2023): November 2023 Issue
Section
Atopic Dermatitis
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

<< < 3 4 5 6 7 8 9 10 11 > >>